Skip to main content
. 2018 Aug;9(4):694–707. doi: 10.21037/jgo.2018.04.02

Table 6. Toxicity profile of standard and modified FOLFIRINOX.

Event Toxicity, n (%) P
Standard FOLFIRINOX$ (N=59) Modified FOLFIRINOX (N=44)
Any G3–4 toxicity 21 (35.6) 16 (36.4) 1.00
Non-hematologic toxicity
   Nausea 2 (3.4) 1 (2.3) 1.00
   Vomiting 2 (3.4) 1 (2.3) 1.00
   Constipation 0 (0.0) 2 (4.5) 0.18
   Diarrhea 1 (1.7) 2 (4.5) 0.57
   Mucositis 2 (3.6) 1 (2.3) 1.00
   Fatigue 4 (6.8) 1 (2.3) 0.38
   Decreased appetite 1 (1.7) 0 (0.0) 1.00
   Peripheral neuropathy 4 (6.9) 2 (4.5) 1.00
Hematologic toxicity
   Anemia 3 (5.1) 3 (6.8) 1.00
   Leukopenia 1 (1.7) 4 (9.1) 0.16
   Neutropenia 9 (15.3) 7 (15.9) 1.00
   Thrombocytopenia 4 (6.8) 5 (11.4) 0.49
   Febrile neutropenia 2 (3.4) 3 (6.8) 0.64
   Treatment delay 27 (45.8) 21 (47.7) 1.00
   Dose reduction 24 (40.0) 14 (31.8) 0.41
   Severe toxicity 11 (18.6) 14 (31.8) 0.16
   Treatment mortality 0 (0.0) 2 (4.5) 0.18

$, data on toxicity was not available for one patient submitted to treatment with standard FOLFIRINOX.